- Reports: Novartis exits vaccines and animal health while acquiring oncology business from GSK
- Senate passes Drug Quality and Security Act
- Novartis names new head of sales U.S.
- ROUNDTABLE: Pharmacy’s future in sync with technology
- GPhA: FDA’s proposed rule on prescription drug labeling adds $4 billion to healthcare costs
THOUSAND OAKS, Calif. — German drug maker Boehringer Ingelheim will purchase a manufacturing plant from U.S. biotech company Amgen, the two said.
The plant, located in Fremont, Calif., is 100,000 sq. ft. and employs around 360 people. BI has been a contract manufacturer for Amgen for more than 10 years. Financial terms of the deal were not disclosed, though BI said it would purchase “substantially all” of the assets at the plant.
“The technological expertise at Fremont and the state-of-the-art facility will enable us to further strengthen our global contract manufacturing business, including new biological entity process development and manufacturing efforts,” BI board member Wolfram Carius said. “We greatly value our relationship with Amgen and are enthusiastic about joining the San Francisco Bay Area biotechnology community and for the opportunity to better serve our current and future contract manufacturing customers.”